On Thursday 24 October, NHS England has announced that people with cystic fibrosis (CF) living in England who stand to benefit from life-saving drugs Orkambi and Symkevi will receive them as part of a two-year managed access agreement with the manufacturer, Vertex Pharmaceuticals. Find out more about this deal, or look at our frequently asked questions.
The Department of Health in Northern Ireland confirmed its intention to complete a deal with Vertex Pharmaceuticals to make life-saving drugs Orkambi and Symkevi available to eligible people with cystic fibrosis (CF) living in Northern Ireland.
On 12 September 2019, the Scottish Government reached an agreement with Vertex with support from the UK CF Registry and announced a five-year deal that will see access to Orkambi and Symkevi for everyone with cystic fibrosis in Scotland who stand to benefit from the drugs.
Last month, Trust Chief Executive David Ramsden, met with the Welsh Government Minister for Health and Social Services, Vaughan Gething, and received this letter following their discussions.
Since then, the Scottish Medicines Consortium was unable to recommend the medicines Orkambi and Symkevi for routine use by NHS Scotland, which prompted Gething to release this statement clarifying Welsh Government position on the continuing issue of access to cystic fibrosis medicines across the UK and update on the situation in Wales.
We are urging Vertex to get a deal done in each of the four nations. Join us on 27 August for a campaign rally for #LifeSavingDrugsNow near Vertex HQ in Paddington.
For the latest news on our Stopping the Clock campaign and other updates in the CF community, sign up to receive our e-newsletter.